Albany Molecular Research (AMRI) : American Capital Management Inc scooped up 32,730 additional shares in Albany Molecular Research during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 1,336,230 shares of Albany Molecular Research which is valued at $19,134,814.Albany Molecular Research makes up approximately 1.53% of American Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Great West Life Assurance Co Can added AMRI to its portfolio by purchasing 32,774 company shares during the most recent quarter which is valued at $469,324.Palisade Capital Managementnj reduced its stake in AMRI by selling 30,721 shares or 4.36% in the most recent quarter. The Hedge Fund company now holds 673,629 shares of AMRI which is valued at $9,646,367. Albany Molecular Research makes up approx 0.41% of Palisade Capital Managementnj’s portfolio.Ngam Advisors boosted its stake in AMRI in the latest quarter, The investment management firm added 5,831 additional shares and now holds a total of 171,297 shares of Albany Molecular Research which is valued at $2,452,973. Albany Molecular Research makes up approx 0.03% of Ngam Advisors’s portfolio.
Albany Molecular Research opened for trading at $15.37 and hit $15.46 on the upside on Monday, eventually ending the session at $15.4, with a gain of 0.59% or 0.09 points. The heightened volatility saw the trading volume jump to 4,04,105 shares. Company has a market cap of $550 M.
Albany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services (DDS) API and Drug Product. The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. The Company’s manufacturing facilities are situated in various locations in the United States Europe and Asia. The Company provides state-of-the-art facilities and solutions to deliver integrated pharmaceutical drug development programs and services including process research and development pre-formulation and formulation development good laboratory practices (GLP) bioanalytical and separation sciences.